# Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

> **NCT00889616** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 154 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** BSAM2/Alhydrogel + CPG 7909

## Key facts

- **NCT ID:** NCT00889616
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-23
- **Primary completion:** —
- **Final completion:** 2012-07-18
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889616, "Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00889616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*